Orthobiologics Market - Forecasts from 2023 to 2028

The orthobiologics market is estimated to grow at a CAGR of 4.6% during the forecast period

The Orthobiologics market is expected to grow at a steady pace during the forecast period.  Orthobiologics are majorly used to treat acute and chronic conditions related to muscles, bones, joints, and soft tissues. The growing demand for advanced treatment coupled with the improved living standard and increased disposable income are major growth drivers of the orthobiologics market. Additionally, the rising incidents of sports injury and road accidents affecting the bones and joints, bone defects and disorders, and technological advancements are further expected to bolster the orthobiologics market size.

Increasing demand for advanced treatment

The disposable and national income especially for developing countries like India is rising with the growing population improving the living standard. According to the Ministry of Statistics and Programme Implementation, GDP for 2022-23 is estimated to increase and reach Rupees 160.06 lakh crore from Rupees 149.26 lakh crore in 2021-22 in India. The growing population and rising income demand advanced treatment and better facilities for their comfortable medications. Moreover, demand for advanced pain treatment in orthopedics using orthobiologics is expected to increase with the wider range of available products in the market thereby propelling the orthobiologics market.

Increasing bone disease and defects

Bone diseases and defects including osteoarthritis joint pain and peripheral nerve pain are on the surge worldwide. According to the Centers for Disease Control and Prevention, around 20% of US adults suffer from chronic pain. The most common bone diseases are generalized osteoporosis, musculoskeletal disorders, and osteogenesis. According to the World Health Organization, around 1.71 billion people had musculoskeletal conditions in 2019 and it is the major contributor to years lived with disability (YLDs) with an estimated 149 million YLDs accounting for 17% of cases worldwide. The prevalence of bone defects and their adverse affect accounts for the orthobiologics market growth as orthobioloigcs are majorly used in orthopedics and musculoskeletal conditions.

Rising sports and road injury

The rising cases of sports injury and road accidents majorly damaging the bones and joints are the major growth factor for the orthobiologics market. Nearly 1.3 million global deaths occur worldwide annually due to road accidents and approximately 20-50 million people suffer from non-fatal road injury as per the estimates of WHO. Moreover, sports injury causing bone defects and other related problems accounts for larger ortho conditions. For instance, according to John Hopkins around 3.5 million sports-related injuries occur each year in the US with almost 50% of injuries occurring from cycling, and skateboarding. These huge cases of injuries affecting the bones and joints are expected to aid the orthobiologics market size.

Technological advancements and government support

The technological advancements through scientists-based research and experiments are anticipated to bolster the orthobiologics market. For instance, a program under the Advanced Research Projects Agency for Health focused on orthopedic tissue regeneration was launched by the ARPA-H initiative in the US. The economic burden of osteoarthritis in the US exceeds $136 million every year as per the ARPA-H reports. The research launched by the ARPA-H will address the need and cut the economic burden by developing technologies in injectable bone regeneration, injectable cartilage regeneration, and replacement joints made from human bones. This research initiative coupled with new product launches by the market players is anticipated to drive the orthobiologics market positively.

Growing aging population

The aging in people contributes to the number of bones and joint-related problems such as arthritis, osteoporosis, and compression fractures. With the aging population and developing joints and bone problems, it is expected to aid the orthobiologics market during the forecasted period.

North America is one of the significant growth region

The North American region is expected to hold a dominant share in the orthobiologics market owing to the rising bone defects and technological advancements. According to CDC, 24% of all adults are diagnosed with arthritis and related conditions in the US and it is expected to rise to 78 million in 2040. Moreover, new product launches and the presence of market leaders such as Alphatec Spine and Arthrex in the region are further contemplated to drive the orthobiologics market in the region during the forecasted period.

Asia-Pacific is one of the fastest-growing market

Asia-Pacific is expected to contribute significantly to the orthobiologics market during the forecast period owing to a greater number of road accidents, and rising income in the region. According to National Crime Record Bureau, road accidents increased to 1,55,622 in 2021 from 1,33,201 in 2020 in India. Moreover, the technological advancements backed by government support and investment are further expected to drive the orthobiologics market in the region.

Orthobiologics Market Players

• Alphatec Spine Inc. is a global solution and revolutionary provider of spine surgery. The spine approach technologies offered by the company are anterior cervical discectomy and fusion, posterior cervical fusion, prone transpsoas, lateral transpsoas, and others.
• Arthrex is one of the leading medical device and innovation companies in orthopedics. Arthrex develops around 1,000 new products each year with the purpose of helping surgeons in treating their patients better. Orthobiologics products offered by the company are Angel® System, Arthrex ACP® Double-Syringe System, Autograft bone, bone repair kits, and Thrombinator® System.
• Bioventus LLC offers solutions in three segments restorative therapies, pain treatments, and surgical solutions. The product offered by the company is StimRouter for pain management, Duralone, Gelsyn-3, and Supartz FX among others.

Market Developments

• In November 2022, Hippofi launched PURbridge™ active bioglass targeting the spine market. It is a flexible and strong bioactive bridge that provides healing and spans the intended area while maintaining its shape.
• In August 2022, Cleveland Clinic launched the first-ever BMAC Phase III trial of orthobiologics for hip osteoarthritis. BMAC was effective in knee osteoarthritis for pain management and joint function as per the already conducted studies.
• In June 2022, Isotos Biologics launched a lineup of five Influx Fibrant products with 100% cortical allograft. The products are Fibrant pak, Fibrant anchor, Fibrant bullet, Fibrant wrap, and Fibrant boat. The versatility of Fibrant advances patient healing and sets the future path for surgeon needs and application.

Segmentation:

By Product

• Viscosupplementation Products
• DBM
• Synthetic Orthobiologics
• BMP
• Allografts
• PRP
• BMAC

By Application

• Osteoarthritis and Degenerative Arthritis
• Spinal Fusion
• Fracture Recovery
• Soft Tissue Injuries
• Maxillofacial and Dental Applications

By End-User

• Hospitals, Orthopedic Clinics, and Ambulatory Care Centers
• Research and Academic Institutes
• Dental Clinics and Facilities

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others